Background
Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.• Induction Immunosuppression in High-risk Kidney Transplant Recipients., PMID:27041548• Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives., PMID:32520680• The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts., PMID:22813834